If comparisons can be odious, so can assumptions [1]

Seizure

Volumn 5, Issue 3, 1996, Pages 247-248

  Jackson, D ^a   Duthie, T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; LAMOTRIGINE; NEUROTRAK; UNCLASSIFIED DRUG; VIGABATRIN;

CLINICAL TRIAL; COST CONTROL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; FOCAL EPILEPSY; HEALTH ECONOMICS; HUMAN; LETTER; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0029995737     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(96)80045-8     Document Type: Letter

References (7)

1. Ordinary People, A Positive Approach to Epilepsy 1995 Department of Health
2. Joint Government/Pharmaceutical Industry Working Party, UK guidance on good practice in the conduct of economic evaluations of medicines British Journal of Medical Economics 7 1994 63 64
3. Hughes D. Cockerell O.C. A Cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy Seizure 5 1996 89 95
4. Binnie CD. The Efficacy of Lamotrigine Reviews in Contemporary Pharmacotherapy 5 1994 115 122
5. Kilpatrick E.S. Forrest G. Brodie M.J. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study Epilepsia 37 1996 534 538
6. Neurotrack 1995 1996 Hospital Marketing Services Limited
7. Baker G.A. Improved quality of life as an outcome of antiepileptic drug therapy, is it enough? CNS Drugs 3 1995 323 327